A Randomized, Double-blind, Placebo Controlled, Dose Finding Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BPI-3016 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs BPI 3016 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Betta Pharmaceuticals Co Ltd
- 29 Dec 2018 Status changed from not yet recruiting to recruiting.
- 12 Jul 2017 Planned End Date changed from 1 Feb 2019 to 1 Dec 2019.
- 12 Jul 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.